Pharmacokinetics of saquinavir-SGC in HIV-infected pregnant women

HIV Clinical Trials

Volumn 2, Issue 6, 2001, Pages 460-465

  Acosta, E P ^a   Zorilla, C ^a   Van Dyke, R ^a   Bardeguez, A ^a   Smith, E ^a   Hughes, M ^a   Huang, S ^a   Pitt, J ^a   Watts, H ^a   Mofenson, L ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Pharmacokinetics; Pregnancy; Saquinavir

Indexed keywords

ANTIFUNGAL AGENT; COTRIMOXAZOLE; LAMIVUDINE; SAQUINAVIR; VITAMIN; ZIDOVUDINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CASE REPORT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREAM; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EXPOSURE; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERANCE; FEMALE; GESTATION PERIOD; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PHASE 1 CLINICAL TRIAL; PREGNANCY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SIDE EFFECT; UMBILICAL CORD BLOOD;

EID: 0035211283     PISSN: 15284336     EISSN: None     Source Type: Journal    
DOI: 10.1310/PUY3-5JWL-FX2B-98VU     Document Type: Article

References (9)

1. Pharmacokinetic changes during pregnancy and their clinical relevance
2. Pharmacodynamics of HIV-1 protease inhibitors
3. Selecting the optimum dose for a new soft gelatin capsule formulation of saquinavir
4. Determination of saquinavir in human plasma by high-performance liquid chromatography
5. Fortovase (saquinavir)
6. Pilot study of BID and TID combinations of saquinavir-SGC (S), Delavirdine (D), zidovudine (ZDV) and lamivudine (3TC) as initial therapy: Pharmacokinetic interaction between S-SGC and D
7. Safety and efficacy of saquinavir-soft gelatin capsules + zidovudine + optional lamivudine in pregnancy and prevention of vertical transmission
8. Relationships between exposure to saquinavir monotherapy and antiviral response in HIV-positive patients